On January 4, 2019 Lamellar Biomedical Limited (Lamellar), an innovative biotechnology company, pioneering new approaches for the safe and effective transfer of functional nucleic acids, reported that Dr Alec McLean, CEO; Steven Porteous, Head of Clinical and Regulatory and Dr Lynsey Howard, Head of Pre-clinical Development will be attending Biotech Showcase in San Francisco on 7-9 January 2019 (Press release, Lamellar Biomedical, JAN 4, 2019, View Source [SID1234532438]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
During the event the Lamellar team will conduct multiple business development meetings with potential partners and investors to highlight the potential of its cutting-edge LAMELLASOME technology for the delivery of nucleic acid therapeutics (NAT). These meetings will build on the very positive reaction to its LAMELLASOME platform, when it was introduced at BIO-Europe 2018 in Copenhagen in November 2018.
Alec McLean, CEO of Lamellar Biomedical, said, "We were very pleased with the reaction from potential partners and investors when we introduced our LAMELLASOME platform for the safe and effective delivery of nucleic acid therapeutics at BIO-Europe late last year. We are now looking forward to multiple new and follow up meetings in San Francisco reflecting the explosion in the number of novel nucleic-acid based therapeutics being developed for a broad range of diseases. Two key factors limiting their progress, from preclinical promise to clinical reality, are safe and effective delivery. Based on our work to-date, Lamellar is confident that it is in an unique position to unlock this enormous potential of nucleic acid based therapeutics using its LAMELLASOME technology."
Lamellar believes that its LAMELLASOME technology will play a key role in realising the potential of many of the nucleic acids in development, including mRNAs, siRNAs, miRNAs and plasmids, potentially revolutionising the treatment of numerous rare and intractable diseases.
In October 2018, Lamellar filed a patent detailing that it had demonstrated functional target downregulation by a transfected nucleic acid delivered via its LAMELLASOME technology. Lamellar has also shown that LAMELLASOME formulations have been effective in delivering functional nucleic acids to a range of cell types including macrophages, human pulmonary fibroblasts and human dendritic cells.
Crucially, all transfected cells types have exhibited very high cell viability and maintenance of cell phenotype/function. Lamellar’s LAMELLASOME technology is entirely novel and does not utilise viral vectors or cationic or divalent ion-associated liposomal systems.
Lamellar is also developing its own pipeline of nucleic-acid based therapeutics, the most advanced of which target two areas of unmet clinical need: Idiopathic Pulmonary Fibrosis and Cystic Fibrosis.
Lamellar is currently completing in-vivo models to demonstrate safe and effective pulmonary delivery and transfection of microRNA(s) prior to executing the final proof of concept efficacy study for its Idiopathic Pulmonary Fibrosis microRNA product in Q1 2019. These studies will be designed to show the performance of LAMELLASOME IPF-NA product in-vivo as well as to demonstrate the unique capabilities of LAMELLASOME nucleic acid transfer technology platform.
The Lamellar team will be available to present the proprietary LAMELLASOME technology to any companies attending Biotech Showcase who see enhanced delivery of their novel nucleic-acid based therapeutics as crucial to their future success.